Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect crossover study of extended-release PHA-022121 40 mg in healthy adults
NL-OMON53489Phase 1Active, not recruiting
- Sponsor
- Pharvaris
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucrictibant in hereditary angioedema (HAE) (2 arms), sponsored by Pharvaris. Primary endpoint: Effect of food on pharmacokinetics of PHA-022121 and metabolites. Started Jan 2023; status: active, not recruiting.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON53489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53489.